{"result": "{\n    \"title\": \"Global Clinical Trials on Septic Shock: PLACEBO vs DROTAA\",\n    \"summary\": \"This report examines the interconnected roles of PLACEBO and DROTAA within clinical trials focused on septic shock treatment. It highlights the global scale of these studies, involving multiple continents and countries, and assesses the impact of these substances on patient outcomes. The findings underscore the critical importance of PLACEBO in establishing treatment efficacy and the ultimate determination of DROTAA's ineffectiveness in improving septic shock patient survival rates.\",\n    \"rating\": 7.5,\n    \"rating_explanation\": \"The impact severity rating is high due to the significant implications of these clinical trials on future treatment protocols for septic shock.\",\n    \"findings\": [\n        {\n            \"summary\": \"PLACEBO's pivotal role in clinical research\",\n            \"explanation\": \"PLACEBO serves as a fundamental control mechanism in clinical trials, particularly those assessing the efficacy of treatments for septic shock and severe sepsis. Its use allows for the unbiased comparison of active medication effects, such as those of hydrocortisone and fludrocortisone, against a neutral standard. This methodology is crucial for validating the therapeutic benefits of new treatments. The widespread application of PLACEBO across various studies emphasizes its indispensable role in clinical research, ensuring that observed patient improvements are directly attributable to the treatment under investigation [Data: Entities (12), Relationships (16, 117, 110, 105, 106, +more)].\"\n        },\n        {\n            \"summary\": \"DROTAA's journey from approval to disapproval\",\n            \"explanation\": \"Initially approved for treating septic shock, DROTAA was subjected to rigorous clinical trials to evaluate its effectiveness in reducing mortality among critically ill adults. Despite high expectations, comprehensive analyses concluded that DROTAA does not offer a survival advantage for septic shock patients. This outcome not only highlights the challenges in developing effective septic shock treatments but also underscores the importance of PLACEBO-controlled trials in accurately assessing treatment efficacy. The findings from these trials have significant implications for medical practice and patient care, steering future research directions away from DROTAA towards more promising treatments [Data: Entities (11), Relationships (12, 98, 90, 100, 101)].\"\n        },\n        {\n            \"summary\": \"Global participation in clinical trials\",\n            \"explanation\": \"The clinical trials involving PLACEBO and DROTAA spanned multiple continents and countries, including Europe, North America, South America, India, Australia, and New Zealand. This global effort underscores the universal challenge posed by septic shock and the collective search for effective treatments. The diverse geographic locations of trial sites enhance the generalizability of the findings, making the conclusions drawn from these studies relevant to a broad patient population. Such widespread participation also reflects the international collaboration essential for advancing medical research and improving global health outcomes [Data: Entities (13, 14, 15, 18), Relationships (102, 103, 104, 107, 94, 95, +more)].\"\n        },\n        {\n            \"summary\": \"The impact of serious and nonserious adverse events\",\n            \"explanation\": \"The recording of serious and nonserious adverse events during the trials provides critical insights into the safety profiles of DROTAA and PLACEBO treatments. These data points are essential for understanding the risks associated with each treatment option, informing both clinical decision-making and patient care strategies. The comparison of adverse event rates between the DROTAA and PLACEBO groups highlights the importance of safety considerations in the evaluation of any treatment's overall efficacy and acceptability [Data: Entities (23, 24), Relationships (100, 101)].\"\n        },\n        {\n            \"summary\": \"The role of the Central Randomization Center\",\n            \"explanation\": \"The Central Randomization Center played a key role in maintaining the integrity of the clinical trials by ensuring the random and blind assignment of patients to treatment or PLACEBO groups. This process is fundamental to the scientific rigor of clinical research, preventing bias in treatment allocation and outcome assessment. The center's operations facilitated the fair comparison of DROTAA and PLACEBO effects, contributing to the reliability and validity of the trial results. The meticulous design and execution of these trials, as evidenced by the involvement of the Central Randomization Center, are critical for advancing our understanding of effective septic shock treatments [Data: Entities (174), Relationships (114, 417)].\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n12,PLACEBO,\"PLACEBO is a control substance widely used in clinical trials to assess the effectiveness of various treatments, particularly in the context of septic shock and severe sepsis. It serves as a benchmark against which the effects of corticosteroids, such as hydrocortisone and fludrocortisone, are compared. In these studies, PLACEBO is typically administered in the same manner as the active medication, often consisting of 0.9 percent saline with or without 0.1 percent human serum albumin, to ensure that the comparison between the treatment and control groups is fair and unbiased. This approach allows researchers to accurately determine the therapeutic effect of the active drugs being tested. PLACEBO has been utilized in trials comparing its effects against hydrocortisone in patients with septic shock, including those undergoing mechanical ventilation, and in studies assessing the effectiveness of hydrocortisone plus fludrocortisone. Additionally, it has been used as a control treatment in studies evaluating the efficacy of acetaminophen and in comparison with the DrotAA treatment group. By serving as a control, PLACEBO plays a crucial role in clinical research, helping to validate the results and ensure that any observed effects are truly attributable to the treatment under investigation rather than other variables.\",18\n11,DROTAA,\"DrotAA is a treatment that was initially approved for patients with septic shock. It was the subject of a clinical trial aimed at assessing its effectiveness in reducing mortality among critically ill adults with this condition. In this study, DrotAA was compared to a placebo group, effectively making it the focus of research involving a specific group of patients receiving this treatment. However, despite its initial approval and the hopes pinned on its effectiveness, the study found that DrotAA was not beneficial for patients with septic shock. This conclusion was drawn from a comprehensive analysis of its impact, indicating that the treatment does not offer the expected survival advantage for those critically ill with septic shock.\",13\n174,CENTRAL RANDOMIZATION CENTER,\"The facility responsible for the random assignment of patients to either the drotrecogin alfa activated treatment or placebo in a 1:1 manner, ensuring the blinding of treatment assignments\",2\n13,EUROPE,A continent where a significant portion of the study's patients were recruited,2\n18,INDIA,A country where a portion of the study's patients were recruited,2\n21,\"MAY 12, 2010\",No Description,2\n14,NORTH AMERICA,A continent where a portion of the study's patients were recruited,2\n15,SOUTH AMERICA,A continent where a portion of the study's patients were recruited,2\n23,SERIOUS ADVERSE EVENTS,\"Recorded incidents of significant negative outcomes in patients during the clinical trial, used to evaluate the safety of DrotAA treatment\",1\n24,NONSERIOUS BLEEDING EVENTS,\"Less severe bleeding incidents recorded among patients in the clinical trial, comparing those treated with DrotAA to those receiving a placebo\",1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\n16,SEPTIC SHOCK,PLACEBO,\"In the study of treating septic shock, a placebo was utilized as a control to compare its effects against corticosteroids. The use of placebos was crucial in assessing the effectiveness of corticosteroids in treating patients with septic shock. This approach allowed researchers to establish a baseline for the treatment's efficacy, ensuring that any observed improvements in patients' conditions could be attributed to the corticosteroids rather than other variables. The consistent use of a placebo as a control across these studies highlights its importance in clinical research, particularly in the context of evaluating new treatments for septic shock.\",95\n12,SEPTIC SHOCK,DROTAA,\"DrotAA, once an approved treatment for septic shock, was subjected to a clinical trial aimed at assessing its effectiveness in reducing mortality among critically ill adults with this condition. However, it was ultimately found not to be beneficial for patients suffering from septic shock.\",90\n117,PLACEBO,SEVERE SEPSIS,A placebo was used as a control in studying the treatment of severe sepsis,40\n98,DROTAA,PLACEBO GROUP,The effectiveness of DrotAA was compared to that of the placebo group in a clinical trial involving critically ill adults with septic shock,36\n90,DROTAA,PLACEBO,DrotAA and Placebo groups were compared in a clinical study to assess treatment effects,31\n116,PLACEBO,DROTRECOGIN ALFA ACTIVATED,Patients who received drotrecogin alfa activated showed greater decreases in D-dimer and interleukin-6 levels than those who received placebo,30\n110,PLACEBO,ADRENAL TRIAL,Placebo was used as a control in the ADRENAL trial to compare its effects against hydrocortisone,28\n105,PLACEBO,AUSTRALIA,\"In the study, the Placebo group included patients who were recruited from various locations, including Australia. Specifically, Placebo was assigned to patients located in medical-surgical Intensive Care Units (ICUs) across Australia. This indicates that a significant part of the research involving Placebo took place within Australian medical facilities, focusing on patients in critical care settings.\",27\n106,PLACEBO,NEW ZEALAND,\"In the study, the Placebo group included patients who were recruited from New Zealand, indicating that a portion of the participants came from this country. These patients were assigned Placebo as part of their treatment in medical-surgical Intensive Care Units (ICUs) across New Zealand. This approach was integral to the research design, highlighting New Zealand's contribution to the study through the participation of its ICUs and the recruitment of local patients for the Placebo group.\",26\n94,DROTAA,AUSTRALIA,A portion of DrotAA group's patients were recruited from Australia,22\n115,PLACEBO,\"COVANCE CENTRAL LAB SERVICES, INDIANAPOLIS\",\"Covance Central Lab Services, Indianapolis, performed blood assays to measure the effects of placebo\",22\n95,DROTAA,NEW ZEALAND,A portion of DrotAA group's patients were recruited from New Zealand,21\n111,PLACEBO,UNITED KINGDOM,The United Kingdom hosted trial sites where patients were assigned to receive placebo,21\n112,PLACEBO,SAUDI ARABIA,Saudi Arabia hosted trial sites where patients were assigned to receive placebo,21\n114,PLACEBO,CENTRAL RANDOMIZATION CENTER,Placebo was assigned to patients through the Central Randomization Center as part of the study's control group protocol,20\n102,PLACEBO,EUROPE,A significant portion of Placebo group's patients were recruited from Europe,20\n107,PLACEBO,INDIA,A portion of Placebo group's patients were recruited from India,20\n108,PLACEBO,\"MAY 12, 2010\",\"Sample size increase decision on May 12, 2010, affected the Placebo group\",20\n103,PLACEBO,NORTH AMERICA,A portion of Placebo group's patients were recruited from North America,20\n104,PLACEBO,SOUTH AMERICA,A portion of Placebo group's patients were recruited from South America,20\n109,PLACEBO,O'BRIEN AND FLEMING,The O'Brien and Fleming method was used to analyze the effectiveness of placebo in the study,20\n113,PLACEBO,MANAGEMENT COMMITTEE,The Management Committee reviewed results from the study involving placebo without knowing the group assignments,20\n99,DROTAA,PROTEIN C,\"The study measured the effect of DrotAA on Protein C activity, finding a significant increase in the DrotAA group compared to the placebo group\",16\n91,DROTAA,EUROPE,A significant portion of DrotAA group's patients were recruited from Europe,15\n92,DROTAA,NORTH AMERICA,A portion of DrotAA group's patients were recruited from North America,15\n93,DROTAA,SOUTH AMERICA,A portion of DrotAA group's patients were recruited from South America,15\n96,DROTAA,INDIA,A portion of DrotAA group's patients were recruited from India,15\n97,DROTAA,\"MAY 12, 2010\",\"Sample size increase decision on May 12, 2010, affected the DrotAA group\",15\n417,DROTRECOGIN ALFA ACTIVATED,CENTRAL RANDOMIZATION CENTER,Drotrecogin alfa activated was assigned to patients through the Central Randomization Center as part of the study's treatment protocol,14\n100,DROTAA,SERIOUS ADVERSE EVENTS,The occurrence of serious adverse events was compared between patients receiving DrotAA and those in the placebo group,14\n101,DROTAA,NONSERIOUS BLEEDING EVENTS,Nonserious bleeding events were more common in patients treated with DrotAA than in those receiving placebo,14\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "gpt-4-turbo-preview", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": 1}, "history": null}